Huntington National Bank Has $48.96 Million Stock Holdings in Abbott Laboratories $ABT

Huntington National Bank cut its stake in Abbott Laboratories (NYSE:ABT) by 2.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 390,804 shares of the healthcare product maker’s stock after selling 8,660 shares during the period. Huntington National Bank’s holdings in Abbott Laboratories were worth $48,964,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ABT. Harbor Capital Advisors Inc. acquired a new position in Abbott Laboratories in the 4th quarter valued at $27,000. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the 3rd quarter valued at $31,000. Bridge Generations Wealth Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at $33,000. Finally, Leonteq Securities AG acquired a new position in Abbott Laboratories in the 4th quarter valued at $35,000. 75.18% of the stock is owned by institutional investors and hedge funds.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott won FDA clearance and EU CE Mark approval for Ultreon 3.0, an AI-powered coronary imaging tool that helps guide artery stent placement, which could support future med-tech growth. Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement
• Positive Sentiment: The company secured CE Mark for Libre Duo, the world’s first dual glucose-ketone sensing technology, expanding its diabetes care lineup and potentially strengthening its CGM franchise. Abbott secures CE Mark for world’s first dual glucose-ketone sensing technology for people with diabetes
• Positive Sentiment: Updated American Cancer Society guidelines reaffirmed Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options, reinforcing Abbott’s position in cancer diagnostics. ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
• Neutral Sentiment: Abbott’s diagnostics unit showed mixed first-quarter trends, with core lab growth offset by weakness in China and softer respiratory testing demand, suggesting an uneven outlook in that segment. How Abbott’s Diagnostics Unit Is Shaping Up Through the Rest of 2026
• Negative Sentiment: Goldman Sachs lowered its price target on Abbott to $113 from $121, even while maintaining a buy rating, adding some caution around near-term upside. Goldman Sachs adjusts price target on Abbott Laboratories to 113 from 121, maintains buy rating
• Negative Sentiment: Separately, commentary highlighted headwinds in Abbott’s nutrition business, which may be weighing on investor sentiment. Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president owned 146,377 shares in the company, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,055 shares of company stock worth $353,097 over the last three months. 0.46% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ABT shares. Bank of America lowered their price target on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Stifel Nicolaus lowered their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Leerink Partners lowered their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a report on Tuesday, April 21st. The Goldman Sachs Group lowered their price target on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday. Finally, Royal Bank Of Canada lowered their price target on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $119.09.

Abbott Laboratories Trading Down 1.1%

Shares of ABT stock opened at $85.70 on Thursday. The firm has a market capitalization of $149.27 billion, a P/E ratio of 24.00, a P/E/G ratio of 1.45 and a beta of 0.65. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock’s fifty day simple moving average is $95.41 and its 200 day simple moving average is $111.15.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.Abbott Laboratories’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.